Hiring in life sciences? Share your open positions with our professional community. Read more Close

Advertisement

CRISPR opens the door to targeted therapy against glioblastoma (Review).

Created on 13 Nov 2026

Authors

Chunzhi Zhang, Yixin Zhang, Nachuan Song, Le Zhang, Yunying Zhao, Chi Yao

Published in

International journal of oncology. Volume 69. Issue 6. Epub Nov 13, 2026.

Abstract

The progression in molecular understanding of glioblastoma (GBM) enables the identification of key therapeutic targets, allowing the advances of targeted therapy in GBM. However, to date, most clinical trial results have been disappointing. The clustered regularly interspaced short palindromic repeats (CRISPR) system is a revolutionary genome‑editing tool that has the potential to improve basic research and therapy for GBM. In the present review, the current status and challenges of targeted therapy in GBM are examined. As a potential approach to address the challenges, the development process and application scope of CRISPR are investigated. Furthermore, the application of CRISPR in the study of GBM is explored, mainly by conducting CRISPR screens and employing CRISPR to target genes associated with the malignant phenotype of GBM. Finally, delivery of CRISPR/CRISPR‑associated protein 9 (Cas9) for the treatment of GBM is briefly reviewed.

PMID:
43023242
Bibliographic data and abstract were imported from PubMed on 13 Nov 2026.

Read full publication at:
Please sign in to see all details.

Advertisement

Stats

  • Community rating n/a 0 votes
  • Reviewers' rating n/a 0 votes
  • Your rating

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

  • Recommendations n/a n/a positive of 0 vote(s)
  • Views 13
  • Comments 0

Recommended by

  • No recommendations yet.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.

Advertisement